CLINICAL_TRIALS
trial_result
· 2019-01-23
Clinical Trial Update: Exploratory Study to Evaluate the Effect of SYN111 (Rufinamide) in Patients With Generalized Anxiety Disorder (GAD) [Phase 2]
Summary
Phase 2 exploratory trial evaluating SYN111 (Rufinamide) in generalized anxiety disorder has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biotie Therapies Inc. | Conditions: Generalized Anxiety Disorder | Phase 2 | Status: COMPLETED | Results posted: 2019-01-23